Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 20, 2017British Journal of HaematologyOpen Access

Validation of the NCCN ‐ IPI for diffuse large B‐cell lymphoma ( DLBCL ): the addition of β2‐microglobulin yields a more accurate GELTAMO ‐ IPI

View Full Paper
Ask AI
Bookmark
Share

Authors

CMCarlos MontalbánThe University of Texas MD Anderson Cancer CenterADAntonio Díaz‐LópezMD Anderson Cancer Center MadridIDIván DlouhyFundación Pethema

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Montalbán et al. (2017) studied this question.

synapsesocial.com/papers/6ab4d24ce006d6a2484d1ceehttps://doi.org/10.1111/bjh.14489
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone2010 · 57 citations
  2. 2An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era2013 · 967 citations
  3. 3Prognosis and prognostic research: validating a prognostic model2009 · 1,471 citations
  4. 4Intensification treatment based on early FDG ‐ PET in patients with high‐risk diffuse large B‐cell lymphoma: a phase II GELTAMO trial2014 · 46 citations
  5. 5The 2016 revision of the World Health Organization classification of lymphoid neoplasms2016 · 7,961 citations